The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100®)

Clinical and Applied Thrombosis/Hemostasis

Volumn 5, Issue 2, 1999, Pages 122-130

  Kottke Marchant, Kandice ^a   Powers, James B ^a   Brooks, Linda ^a   Kundu, Sourav ^b   Christie, Douglas J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Dade Behring Inc   (United States)

Author keywords

Abciximab (ReoPro); Antiplatelet drugs; Aspirin; Glycoprotein IIb IIIa antagonists; Platelet aggregation; Platelet function analyzer

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; HEPARIN; TICLOPIDINE;

ANALYTICAL ERROR; ANTICOAGULANT THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DIAGNOSTIC ACCURACY; EVALUATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0032890704     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969900500209     Document Type: Article

References (24)

1. Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100® system. Semin Thromb Hemost 1995; 21:113.
2. Kundu SK, Heilmann EJ, Sio R, et al. Characterization of an in vitro platelet function analyzer, PFA-100®. Clin Appl Thromb Hemost 1996;2:241.
3. Kratzer MAA, Born GVR. Simulation of primary haemostasis in vitro. Haemostasis 1985;15:357.
4. Kundu SK, Heilmann EJ, Sio R, et al. Description of an in vitro platelet function analyzer-PFA 100®. Semin Thromb Hemost 1995; 21:106.
5. Fressinaud E, Veyradier A, Truchaud F, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998;91:1325.
6. Mammen EF, Comp PC, Gosselin R, et al. PEA-100® System. A new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195.
7. Block PC. Mechanism of transluminal angioplasty. Am J Cardiol 1984;53:59C.
8. Farb A, Virmani R, Atkinson JB, Kolodgie FD. Plaque morphology and pathologic changes in arteries from patients dying after coronary balloon angioplasty. J Am Coll Cardiol 1990;16:1421.
9. Harrington RA. Trials of novel antiplatelet agent. J Myocard Ischemia 1994;6:20.
10. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084.
11. Ohman EM, Harrington RA, Lincoff AM, et al. Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. Eur Heart J 1994;16:50.
12. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956.
13. Barragan P, Sainsous J, Silvestri M, et al. Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting. Cathet Cardiovasc Diagn 1994;32:133.
14. Lablance J-M, McFadden EP, Bonnet J-L, et al. Combined antiplatelet therapy with ticlopidine and aspirin: a simplified approach to intracoronary stent management. Eur Heart J 1996;17:1373.
15. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222.
16. Tcheng JE. Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trials in interventional cardiology. Thromb Haemost 1997; 78:205.
17. Muller M, Becker-Hagendorf K, Westrup D, et al. PFA-100™ system: a sensitive screening test for platelet-related hemostasis defects. Ann Hematol 1997;74(suppl II):72.
18. Simpfendorfer C, Kottke-Marchant K, Lowrie M, et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997; 96:76.
19. Cannon CP, McCabe CH, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist. Sibrafiban, in patients after an acute coronary syndrome. Results of the TIMI 12 trial. Circulation 1998;97:340.
20. Vorcheimer DA, Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety. Circulation 1998;97:312.
21. Heptinstall S, May JA, Glenn JR, et al. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Thromb Haemost 1995;74:1310.
22. Hardisty RM, Powling MJ, Nokes TJC. The action of ticlopidine on human platelets: studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost 1990; 64:150.
23. Nichols AB, Owen J, Grossman B, et al. Effect of heparin bond on catheter-induced fibrin formation and platelet activation. Circulation 1984;70:843.
24. Eika C. The platelet aggregating effect of eight commercial heparins. Scand J Haematol 1972;9:480.